Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease

Behavioural Pharmacology

Volumn 23, Issue 4, 2012, Pages 426-433

  Price, Diana L ^a,b   Bonhaus, Douglas W ^a,b   McFarland, Krista ^a  

^a ACADIA PHARMACEUTICALS INC   (United States)

^b Neuropore Therapies Inc   (United States)

Author keywords

Alzheimer's disease psychosis; amyloid b; animal model; serotonin

Indexed keywords

PIMAVANSERIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PHENOTYPE;

ALZHEIMER DISEASE; AMPHETAMINE; AMPHETAMINES; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DRUG INVERSE AGONISM; MALE; MICE; PIPERIDINES; PSYCHOTIC DISORDERS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; UREA;

EID: 84863811605     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283566082     Document Type: Article

References (48)

1. Abbas A, Roth BL (2008). Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother 9:3251-3259.
2. Agid O, Kapur S, Remington G (2008). Emerging drugs for schizophrenia. Expert Opin Emerg Drugs 13:479-495.
3. Ballard C, Howard R (2006). Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 7:492-500. (Pubitemid 44012289)
4. Ballard C, Creese B, Corbett A, Aarsland D (2011). Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf 10:35-43.
5. Carlsson ML, Martin P, Nilsson M, Sorensen SM, Carlsson A, Waters S, et al. (1999). The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist than dopamine agonist-induced hyperactivity in mice. J Neural Transm 106:123-129. (Pubitemid 29137509)
6. Creese I, Burt DR, Snyder SH (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483.
7. Dall'Igna OP, Hoffmann A, da Silva AL, Souza DO, Lara DR (2004). Beta-amyloid treatment sensitizes mice to amphetamine-induced locomotion but reduces response to caffeine. Neurodegener Dis 1:38-43. (Pubitemid 38581677)
8. FantegrossiWE, Simoneau J, Cohen MS, Zimmerman SM, Henson CM, Rice KC, et al. (2010). Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4- iodoamphetamine-elicited head twitch behavior in mice. J Pharmacol Exp Ther 335:728-734.
9. FDA (2005). Deaths with antipsychotics in elderly patients with behavioral disturbances. Public Health Advisory.
10. Fernandez M, Gobartt AL, Balana M (2010). Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment. BMC Neurol 10:87.
11. Fletcher PJ, Grottick AJ, Higgins GA (2002). Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology 27:576-586.
12. Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT, et al. (2007). ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J Pharmacol Exp Ther 322: 862-870. (Pubitemid 47105818)
13. Geyer MA, Swerdlow NR (2001). Measurement of startle response, prepulse inhibition, and habituation. Curr Protoc Neurosci, Chapter 8, Unit 8.7.
14. Ichikawa J, Dai J, Meltzer HY (2002). 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Res 939:34-42. (Pubitemid 34518587)
15. Kowall NW, McKee AC, Yankner BA, Beal MF (1992). In vivo neurotoxicity of beta-amyloid [beta(1-40)] and the beta(25-35) fragment. Neurobiol Aging 13:537-542.
16. Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST (1999). Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 56:1266-1272. (Pubitemid 29473220)
17. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC (2000). Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 157:708-714. (Pubitemid 30249648)
18. Martin P,Waters N,Waters S, Carlsson A, Carlsson ML (1997). MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. Eur J Pharmacol 335:107-116. (Pubitemid 27450474)
19. Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM, Gainetdinov RR, et al. (2008). Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA 105:13656-13661.
20. Maurice T, Lockhart BP, Privat A (1996). Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706:181-193. (Pubitemid 26048681)
21. McFarland K, Price DL, Bonhaus DW (2011). Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease. Behav Pharmacol 22:681-692.
22. Meltzer HY (2000). An atypical compound by any other name is still a. Psychopharmacology 148:16-19. (Pubitemid 30062466)
23. Meltzer HY, Matsubara S, Lee JC (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246.
24. Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al. (2010). Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology 35:881-892.
25. Meunier J, Ieni J, Maurice T (2006). The anti-amnesic and neuroprotective effects of donepezil against amyloid [beta]25-35 peptide-induced toxicity in mice involve an interaction with the [sigma]1 receptor. Br J Pharmacol 149:998-1012. (Pubitemid 44950803)
26. Paulsen JS, Salmon DP, Thal LJ, Romero R,Weisstein-Jenkins C, Galasko D, et al. (2000). Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 54:1965-1971. (Pubitemid 30327121)
27. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW (1993). Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13:1676-1687. (Pubitemid 23095409)
28. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW (1995). Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 64:253-265.
29. Pritchard AL, Harris J, Pritchard CW, Coates J, Haque S, Holder R, et al. (2008). Role of 5HT2A and 5HT2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease. Neurobiol Aging 29:341-347. (Pubitemid 351215579)
30. Proitsi P, Lupton MK, Reeves SJ, Hamilton G, Archer N, Martin BM, et al. (2012). Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiol Aging 33:791-803.
31. Quaranta D, Bizzarro A, Marra C, Vita MG, Seripa D, Pilotto A, et al. (2009). Psychotic symptoms in Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene: evidence for an association. J Alzheimers Dis 16:173-180.
32. Rocca P, Leotta D, Liffredo C, Mingrone C, Sigaudo M, Capellero B, et al. (2010). Neuropsychiatric symptoms underlying caregiver stress and insight in Alzheimer's disease. Dement Geriatr Cogn Disord 30:57-63.
33. Ropacki SA, Jeste DV (2005). Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry 162:2022-2030. (Pubitemid 41598255)
34. Scarmeas N, Brandt J, Albert M, Hadjigeorgiou G, Papadimitriou A, Dubois B, et al. (2005). Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol 62:1601-1608. (Pubitemid 41434568)
35. Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG (1995). The role of 5-HT2A receptors in antipsychotic activity. Life Sci 56:2209-2222.
36. Schneider LS, Dagerman K, Insel PS (2006). Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebocontrolled trials. Am J Geriatr Psychiatry 14:191-210.
37. Selkoe DJ (1991). The molecular pathology of Alzheimer's disease. Neuron 6:487-498.
38. Serretti A, Drago A, De Ronchi D (2007). HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr Med Chem 14:2053-2069. (Pubitemid 47578163)
39. Sharma T (2002). Impact on cognition of the use of antipsychotics. Curr Med Res Opin 18 (Suppl 3):s13-s17.
40. Sinforiani E, Terzaghi M, Pasotti C, Zucchella C, Zambrelli E, Manni R (2007). Hallucinations and sleep-wake cycle in Alzheimer's disease: a questionnairebased study in 218 patients. Neurol Sci 28:96-99. (Pubitemid 46681665)
41. Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al. (2008). Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 23:170-177. (Pubitemid 351308497)
42. Tatsumi H, Nakaaki S, Torii K, Shinagawa Y,Watanabe N, Murata Y, et al. (2009). Neuropsychiatric symptoms predict change in quality of life of Alzheimer disease patients: a two-year follow-up study. Psychiatry Clin Neurosci 63:374-384.
43. Tsuang D, Larson EB, Bole E, Thompson ML, Peskind E, Bowen J, et al. (2009). Visual hallucinations in dementia: a prospective community-based study with autopsy. Am J Geriatr Psychiatry 17:317-323.
44. Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, et al. (2006). Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N- (1-methylpiperidin-4-yl)-N0-(4-(2-methylpropylo xy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine( 2A) receptor inverse agonist. J Pharmacol Exp Ther 317:910-918.
45. Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, et al. (2011). Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry 168:831-839.
46. Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, et al. (2001). 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 299:268-276. (Pubitemid 32905144)
47. Wilkosz PA, Seltman HJ, Devlin B, Weamer EA, Lopez OL, DeKosky ST, et al. (2010). Trajectories of cognitive decline in Alzheimer's disease. Int Psychogeriatr 22:281-290.
48. Youssef HA,Waddington JL (1987). Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand 75:74-77.